TREATMENT FOR GLOMERULONEPHRITIS WITH 2-[4-(7-ETHYL-5H-PYRROLO[2,3-B]PYRAZIN-6-YL)PHENYL]PROPAN-2-OL
A treatment for glomerulonephritis, and other renal dysfunctions using a compound of Formula I is disclosed.
1 . A method of treating glomerulonephritis, comprising administering to a patient in need thereof an effective amount of a compound of Formula I:
or a corresponding N-oxide, prodrug, pharmaceutically acceptable salt or solvate thereof.
2 . A pharmaceutical composition for treating glomerulonephritis, comprising a compound of formula I, or a corresponding N-oxide, prodrug, pharmaceutically acceptable salt or solvate thereof, in combination with a pharmaceutically acceptable excipient.
3 . A method for the treatment of a human or non-human animal patient suffering from, or subject to, a condition that can be ameliorated by the administration of a pharmaceutically effective amount of a compound of formula I:
comprising administering an effective amount of said compound to a patient in need thereof.
4 . A method of treating glomerulonephritis, comprising administering to a patient in need thereof an effective amount of a compound which is a Syk inhibitor.
5 . A method of treating a renal disease, comprising administering to a patient in need thereof an effective amount of a compound of Formula I:
or a corresponding N-oxide, prodrug, pharmaceutically acceptable salt or solvate thereof, wherein the renal disease is selected from: glomerulonephritis, Goodpasture's syndrome, mesangiocapillary glomerulonephritis, post-infectious glomerulonephritis, Henoch-Schönlein purpura, Berger's disease, membranous glomerulonephritis, focal segmental glomerulosclerosis, lupus nephritis, hereditary nephritis, mesangial proliferative glomerulonephritis, thin basement membrane disease, crescentic nephritis, and rapidly progressive glomerulonephritis.
6 . The method according to claim 1 , wherein the compound is in the form of a hydrochloride salt.